Abaloparatide formulations and methods of testing, storing, modifying, and using same
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.
1. A method of analyzing a sample containing abaloparatide comprising using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising an aqueous buffer, wherein said aqueous buffer has a pH range of between 7-9 prior to mixing with any additional mobile phase solvent, wherein analyzing a sample comprises detecting and quantifying the presence of ≤5% w/w beta-Asp10 of the total peptide content.
2. The method of claim 1 , wherein said aqueous buffer has a pH of between 7.5 and 8.5, prior to mixing with any additional mobile phase solvent.
3. The method of claim 2 , wherein said aqueous buffer has a pH of between 7.6 and 8.0, prior to mixing with any additional mobile phase solvent.
4. The method of claim 3 , wherein said aqueous buffer has a pH of about 7.8 prior to mixing with any additional mobile phase solvent(s).
5. The method of claim 1 , wherein said aqueous buffer comprises ammonium phosphate ((NH 4 )H 2 PO 4 ).
6. The method of claim 1 , wherein analyzing the sample comprises detecting and quantifying the presence of ≤1.0% w/w beta-Asp10 of the total peptide content.
7. The method of any one of the preceding claims, wherein the sample containing abaloparatide is a formulated abaloparatide drug product.
8. The method of claim 7 , wherein the sample containing abaloparatide is initially prepared, has been stored for up to 23 months at 2-8° C., has been stored for 23 months at 2-8° C. followed by a month at 20-25° C., or has been stored for 35 months at 2-8° C. followed by a month at 20-25° C.
9. A method of establishing the suitability of a formulated abaloparatide drug product for administration to a subject, the method comprising:
detecting and quantifying the presence of ≤5% w/w beta-Asp10 of the total peptide content in a formulated abaloparatide drug product using an HPLC and/or UPLC using a binary solvent system with a mobile phase comprising an aqueous buffer, wherein said aqueous buffer has a pH range of between 7.5-8.5 prior to mixing with any additional mobile phase solvent.
10. The method of claim 9 , wherein the formulated abaloparatide drug product is an initially prepared, formulated abaloparatide drug product.
11. The method of claim 9 , wherein the formulated abaloparatide drug product has been stored for 23 months at refrigerated conditions, followed by one month at room temperature.
12. The method of claim 9 , wherein the formulated abaloparatide drug product has been stored for 35 months at refrigerated conditions, followed by one month at room temperature.
13. The method of any one of claims 9 - 12 , comprising using a C4 Silicon-based, reverse phase column comprising particles with an average mean particle diameter of less than 3.0 microns.
14. A formulated abaloparatide drug product comprising ≤5% w/w beta-Asp10 of the total peptide content, and an aqueous buffer having a pH from 4.5-5.5, wherein said formulated abaloparatide drug product has an abaloparatide concentration of between 1.8 mg/mL and 2.2 mg/mL, wherein the suitability of the formulated abaloparatide drug product for administration to a subject has been established by a method comprising: detecting and quantifying the presence of ≤5% w/w beta-Asp10 of the total peptide content in the formulated abaloparatide drug product.
15. The formulated abaloparatide drug product of claim 14 , comprising ≤1.0% w/w beta-Asp10 of the total peptide content.